CRISPR Therapeutics CRSP Operating margin

Operating margin at other companies

Ultragenyx PharmaceuticalRARE

-73.6%-7.3pp

Intellia TherapeuticsNTLA

-711.7%-149pp

Allogene TherapeuticsALLO

-1,241,813.6%-2,018,140pp

Beam TherapeuticsBEAM

-226.6%-90.5pp

Prime MedicinePRME

-4,498.1%-1,134pp

RegenxbioRGNX

-94.1%-9.3pp

FAQ

What is CRISPR Therapeutics's operating margin?

CRISPR Therapeutics (CRSP) reported operating margin of -15,754.2% in Q1 2026.

How has CRISPR Therapeutics's operating margin changed year-over-year?

CRISPR Therapeutics's operating margin decreased by 1151.1% year-over-year, from -1,259.2% to -15,754.2%.

What is the long-term trend for CRISPR Therapeutics's operating margin?

Over 3 years (2020 to 2025), CRISPR Therapeutics's operating margin has grown at a -27.3% compound annual growth rate (CAGR), from -49,295.5% to -18,933.6%.

What does operating margin mean?

Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.